CytoDyn (CYDY) Stock Price, News & Analysis

Company Overview

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Key Stats

• Today's Range: $0.25 to $0.30
• 50-Day Range: $0.11 to $0.30
• 52-Week Range: $0.10 to $0.32
• Volume: 4.70 million shs
• Average Volume: 3.66 million shs
• Market Capitalization: $367.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYDY Stock Analysis - Frequently Asked Questions

How have CYDY shares performed this year?

CytoDyn's stock was trading at $0.1097 on January 1st, 2025. Since then, CYDY stock has increased by 172.5% and is now trading at $0.2989.
View the best growth stocks for 2025 here.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) announced its earnings results on Tuesday, April, 13th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01.

How do I buy shares of CytoDyn?

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 4/13/2021
• Today: 2/21/2025
• Next Earnings (Estimated): 4/14/2025
• Fiscal Year End: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CYDY
• Previous Symbol: NASDAQ:CYDY
• CUSIP: 23283M101
• CIK: 1175680
• Web: www.cytodyn.com
• Phone: (360) 980-8524
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,840,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -76.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.35
• Quick Ratio: 0.35

Sales & Book Value

• Annual Sales: $270,000.00
• Price / Sales: 1,362.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.11) per share
• Price / Book: -2.72

Miscellaneous

• Outstanding Shares: 1,230,840,000
• Free Float: 1,224,197,000
• Market Cap: $367.90 million
• Optionable: Not Optionable
• Beta: 0.01